ICI-Chemo 是子宫内膜癌的新标准。
ICI-Chemo New Standard for Endometrial Cancer.
发表日期：2023 Mar 29
作者：
来源：
Cancer Discovery
摘要：
RUBY和NRG-GY018的第III期试验表明，晚期子宫内膜癌的女性，无论是新诊断的疾病还是第一次复发的病例，在标准化疗方案基础上加入PD-1抑制剂，能够获益。添加Dostarlimab或Pembrolizumab显著延长了无进展生存期，总生存期也呈上升趋势。©2023 American Association for Cancer Research.
The phase III RUBY and NRG-GY018 trials indicate that women with advanced endometrial cancer whose disease is newly diagnosed or has recurred for the first time benefit from the combination of a PD-1 inhibitor with standard chemotherapy. Adding either dostarlimab or pembrolizumab significantly prolonged progression-free survival, with overall survival also trending in the right direction.©2023 American Association for Cancer Research.